おかえりなさい
アカウント登録
siteでログインする
siteで登録する
受信トレイを確認する
Veracyte
About
Veracyte develops molecular diagnostic tests to improve patient outcomes and lower healthcare costs.
- 501 - 1000
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $45M
- Industries
- Biotechnology,Health Care,Health Diagnostics
- Founded date
- Jan 1, 2006
- Number Of Employee
- 501 - 1000
- Operating Status
- Active
Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer, and idiopathic pulmonary fibrosis are available to patients, and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 29, 2016 | Post-IPO Debt | $45M | 1 |
|
— | Detail |
| Jun 28, 2013 | Series C | $28M | 1 | — | — | Detail |
| Jun 11, 2010 | Series B | $28M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Post-IPO Debt |
Versant Ventures
|
— | Series C |
